| Literature DB >> 30327560 |
Tyler E Wagner1,2, Jacob R Becraft2,3, Katie Bodner2,3,4, Brian Teague2, Xin Zhang2, Amanda Woo2, Ely Porter2, Bremy Alburquerque3, Brian Dobosh2, Oliwia Andries5,6, Niek N Sanders5,7, Jacob Beal8, Douglas Densmore1,9, Tasuku Kitada10,11, Ron Weiss12,13.
Abstract
Synthetic mRNA is an attractive vehicle for gene therapies because of its transient nature and improved safety profile over DNA. However, unlike DNA, broadly applicable methods to control expression from mRNA are lacking. Here we describe a platform for small-molecule-based regulation of expression from modified RNA (modRNA) and self-replicating RNA (replicon) delivered to mammalian cells. Specifically, we engineer small-molecule-responsive RNA binding proteins to control expression of proteins from RNA-encoded genetic circuits. Coupled with specific modRNA dosages or engineered elements from a replicon, including a subgenomic promoter library, we demonstrate the capability to externally regulate the timing and level of protein expression. These control mechanisms facilitate the construction of ON, OFF, and two-output switches, with potential therapeutic applications such as inducible cancer immunotherapies. These circuits, along with other synthetic networks that can be developed using these tools, will expand the utility of synthetic mRNA as a therapeutic modality.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30327560 DOI: 10.1038/s41589-018-0146-9
Source DB: PubMed Journal: Nat Chem Biol ISSN: 1552-4450 Impact factor: 15.040